Experience of the Application of Ukrain in Oncological Practice in Ukraine
V. S. ZEMSKOV, O. YA. YAREMCHUK, YA. M. SUSAK,* E. R. DENEKA, O. V. KRAVCHENCO, and L. YA. KAMENETS
Department of General Surgery. Department of Oncology. Ukrianian Stale Medical University, Kiev, Ukraine
Starting from 1992, the Departments of General Surgery and Oncology of Ukrainian State Medical University have been carrying out investigations on the application of the preparation Ukrain in oncological patients. Ukrain is a chelidonine thiophosphoric acid derivative. Tris(2-([5bS-(5ba,6b,12ba)]-5b,6,7,12b,13,14-hexahydro-13-methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium-6 ol)ethaneaminil)phosphinesulfide6HCL. Its immunostimulating and antineoplastic properties in vitro, in vivo. and in clinical practice arc widely reflected in the literature (2-4,6). These properties of Ukrain are of particular importance for the Ukraine, which is still suffering the harmful influence of the consequences of the accident at the Chernobyl nuclear power station (prolonged influence of small doses of radiation, accumulation of radionuclides in an organism). These post-accident after-effects lead to damage in the immune T-system and especially in the system of natural killer cells responsible for anticancer and antiviral defense (1,5,7). The opportunity of carrying out this research was granted by the Ukrainian Anticancer Institute, Austria.
The aim of the research was the further study of the action of Ukrain upon oncology patients under conditions of harmful anthropogenic factors.